8
Oct
2024

UGA Biopharma GmbH

Exhibitor at CPHI Milan 2024 stand 20C11, Packaging and Drug Delivery
About Us

We are an experienced contract development organization that provides services across the cell line development for expression of antibodies, enzymes, hormones etc. We additionally offer a wide range of developed and well characterized biosimilar cell lines ready to be employed for up-scaling in a manufacturing process (ready-to-use), and our high-performance cell culture media and feeds. Visit our booth and discover why UGA Biopharma could be your next partner.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • DE
  • 2023
    On CPHI since
  • 1
    Certificates
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Contract Research Organisation (CRO)
Contract Service
Primary activities
Biopharmaceutical
Contract Research Organisation
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 20C11, Packaging and Drug Delivery

Products Featured at CPHI Milan 2024

  • Cell line development services

    Product Cell line development services

    Cell line development services, including molecular cloning, CHO cell line development and lead clone selection, bioprocess optimization, DSP and analytical characterization of the target molecule.



  • Ready to use cell lines

    Product Ready to use cell lines

    Ready to use cell lines
  • Media & Feeds for CHO cell line

    Product Media & Feeds for CHO cell line

    The First CHOice® Medium is a high-performance cell culture medium optimized for mammalian suspension cells ensuring high product quality and cell viability during all cultivation phases. In combination with the First CHOice® Feeds Alpha & Beta, offer a platform to achieve excellent cell growth, an...
  • Ready-to Use CHO cell lines

    Product Ready-to Use CHO cell lines

    UGA Biopharma GmbH offers to their clients so called Ready-to-use Biosimilar Cell Lines. This are in-house developed CHO cell lines stably expressing different biosimilar molecules, that are instantly available for in-licensing. The client profits, because the cell lines are directly available, and develop...